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Cardiogenic cerebral thromboembolism is responsible for 
about 15% of all cases of ischemic stroke-not as many as 
attributed to thrombotic or embolic complications of cere- 
brovascular disease, but still the cause of disabling stroke in 
>75,000 Americans annually (1). As we recently reviewed 
(2), cardiac diseases underlying these events involve atria1 
fibrillation in about half the cases and valvular heart disease 
or left ventricular mural thrombus in the remainder (1,3). 
Sixty percent of emboli of left ventricular origin are a 
consequence of acute myocardial infarction (1,4), account- 
ing for 15,000 to 25,000 embolic strokes each year. Several 
studies suggest that the risk is highest in the first 1 to 3 
months after infarction and perhaps even greater in the first 
10 days for patients with a large anterior infarct who have a 
30% to 40% chance of developing ventricular thrombus and 
about a 5% risk of embolism (4,5). In addition, those who 
survive become part of a larger population of patients with 
chronic ventricular dysfunction in whom the potential for 
embolism is persistent (6). 
Left ventricular thromhus in acute myocardial infarction. 
In patients with myocardial infarction, >90% of ventricular 
thrombi occur when the anterior wall becomes hypokinetic 
or akinetic, enlarging the apical zone of intraventricular 
stasis. Inflammatory changes at the endocardial surface and 
enhanced thrombogenicity are additional reasons throm- 
boembolism occurs most frequently within the first 10 days 
of a coronary event, although the tendency to thrombus 
formation may persist during the first 1 to 3 months. Infarct 
size seems directly related to thromboembolic risk, and the 
incidence of left ventricular thrombus during the early 
postinfarction period exceeds 50% in those with anteroapical 
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infarction, producing peak serum creatine kinase concentra- 
tions >2,000 U/liter (4,5). 
Pathophysiology of cardiogenic thrombwmbolism. The 
pathophysiology involves a balance between the factors 
favoring thrombus formation within the ventricular cavity- 
endocardial injury, regional circulatory stasis and activation 
of the intrinsic coagulation system-and the dynamic forces 
of the circulation that must project thrombotic material out 
of the ventricular cavity and into the systemic circulation to 
produce clinical morbidity. For example, when left ventric- 
ular aneurysm is present remote from myocardial infarction, 
mural thrombus formation is frequent, but the embolic risk is 
low. On the other hand, embolism seems to occur most 
frequently in patients with echocardiographically evident 
mobility of the thrombotic mass within the ventricular cham- 
ber (5,7,8). Overall, the published data suggest that cerebral 
embolism occurs clinically in about 10% of those with 
echocardiographically evident mural thrombus within the 
first 3 months after myocardial infarction, although it is often 
difficult to classify acute ischemic events as embolic in 
patients with advanced atherosclerotic disease. 
Treatment. The effect of antithrombotic medication on 
the occurrence and natural history of left ventricular throm- 
boembolism is difficult to surmise. In the past 5 years, 
several studies (9-l 1) involving patients with acute myocar- 
dial infarction have addressed the relation between cerebral 
embolism and left ventricular thrombus detected by echo- 
cardiography. Although no clinical trial has had sufficient 
sample size to detect significant differences in embolism, in 
aggregate thrombus formation has been reduced by >50% 
with anticoagulant therapy (12-14). Other trials involving 
patients with acute inferior and anterior myocardial infarc- 
tion demonstrated that initial treatment with heparin fol- 
lowed by administration of an oral anticoagulant agent for a 
few months in relatively low doses reduced the occurrence 
rate of cerebral embolism to 1% from the 3% rate obtained 
with no anticoagulation (15). A recently reported random- 
ized prospective trial (16), involving more than 200 patients 
with a large anterior infarct, found that thrombus was 
detected in 11% of the group given the higher heparin dose of 
12,500 U every 12 h compared with 32% of those receiving 
the lower dose of 5,000 U every 12 h during the first 10 days. 
The impact of adding platelet inhibitor medication to an 
anticoagulant agent has not been evaluated in a large scale 
study (17). 
Present study. In this issue of the Journal, Nihoyannop- 
oulos et al. (18) offer data that challenge several basic 
assumptions regarding left ventricular mural thrombus for- 
mation after acute myocardial infarction. Because the prog- 
nosis for survival was better in patients with evidence of 
thrombus formation and the risk of stroke was no greater 
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than in those without thrombus, the authors conclude that 
such thrombi may offer a protective effect and that an- 
tithrombotic medication may not be needed in such patients. 
Three aspects of the report (18) warrant particular com- 
ment. First, each of the patients received antithrombotic 
medication in the form of heparin subcutaneously plus 
aspirin and dipyridamole orally; one cannot be sure what 
impact this intervention may have had on the natural history 
of thromboembolic events. Second, early in-hospital mortal- 
ity was greater in patients without a thrombus than in those 
in whom a thrombus occurred, leading the authors to suggest 
that the mural thrombus might offer mechanical support to 
infarcted myocardium and protect against rupture. Although 
this hypothesis is intriguing, it may take about a week for 
thrombus to be detectable by standard transthoracic echo- 
cardiography. In the study by Nihoyannopoulos et al. (18) 5 
(42%) of 12 early deaths occurred within 3 days of admis- 
sion, yet a detectable thrombotic mass did not usually 
develop before the 6th day. An alternative hypothesis. 
therefore, is that patients at highest risk may not have 
survived long enough for ventricular thrombus to form (19). 
The third aspect is that a clear-cut stroke occurred in only 
one patient before hospital discharge, and this patient had an 
inferior myocardial infarction without evident intraventricu- 
lar thrombus. Neurologic symptoms in 11% of the other 
patients were transient and difficult to interpret, but no 
infarct was apparent on computed tomographic scans of the 
brain in these patients. 
prophylactic anticoagulant medication in patients without 
thrombus formation and when to withdraw anticoagulant 
medication when thrombus is identified-at the time of the 
patient’s discharge from the hospital or after 3 months? 
Another issue is whether thrombolytic therapy will, in fact, 
reduce the likelihood of developing ventricular thrombus. 
Then there is the problem of quantifying the persistent risk 
of thromboembolic events in those who survive myocardial 
infarction with chronic left ventricular dysfunction (6). 
In addition to the problem of left ventricular thromboem- 
bolism, patients with myocardial infarction present a com- 
plex situation in which antithrombotic therapy may have 
implications for the prevention of future coronary events. 
The best approach for the prevention of both left ventricular 
thrombus and complications of underlying coronary athero- 
sclerotic disease remains to be defined on the basis of a 
prospective clinical trial. The advocation of “masterly inac- 
tivity” by Nihoyannopoulos et al. (18) seems premature. 
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